What does it look like when a decade of ketamine therapy experience, a government-issued psychedelic research license in the Caribbean, and the world's most advanced DMT infusion protocol converge in a single clinical operation? On this episode of Inside the Revival, host Jim Tate engages Charles Patti, co-founder and Chief Visionary Officer of Eleusis Mind, operating in Saint Vincent and the Grenadines, to explore extended-state DMT (DMTx) research as it is actually being practiced, not theorized.

Patti traces the scientific lineage of DMTx from Dr. Rick Strassman's DEA-approved human trials at the University of New Mexico in the 1990s through Dr. Andrew Gallimore and Dr. Chris Timmermann's landmark pilot study at Imperial College London, and into Eleusis Mind's applied research protocol, i.e., 150-plus sessions to date, with 78% of participants reporting entity contact experiences. He details the center's tiered immersion programs (4-day/3-night Essential and 6-day/5-night Complete), its rigorous screening infrastructure, its SSRI and contraindication protocols, and its use of AI-assisted journey report analysis to map the DMT state. He also locates DMTx within the fast-evolving U.S. regulatory landscape, including President Trump's April 2026 executive order directing $50 million toward psychedelic research and makes the case for DMT and ketamine as the molecules most suited to scalable clinical application.

The Age of the Sage: Psilocybin, Women Over 60, and the Medicine That Meets Them Where They Are by PsylenciaMedia

A Veteran's Mission to Redesign Immersive Sound Therapy

What happens when the music meant to support healing becomes its own source of disruption? Rogers Masson knows firsthand. A U.S. Army veteran and Grammy-voting music producer who spent over three decades living with PTSD, Masson entered the MAPS/FDA expanded access MDMA-assisted therapy trials at the Pearl Institute in Asheville, North Carolina — and emerged as Patient 001 with a mission. The standard therapeutic playlists he encountered during treatment were, by his account and his therapists' own admission, a known problem. Rather than accept it, Masson paused a 25-year career and built PsySonics: immersive, psychoacoustic sound engineered from the ground up for MDMA, ketamine, and psilocybin sessions. On this episode of Inside the Revival, host Jim Tate explores the science, design, and personal conviction behind a tool now used in clinical trials and trusted therapeutic practices across the psychedelic ecosystem.

On this episode, host Jim Tate sits with Christopher James Cramer, director and producer of Journeys, the documenary. We discuss what it takes to make an honest documentary about psilocybin therapy, one that neither evangelizes nor pathologizes, but simply illuminates? Independent filmmaker. From a baby shower conversation that changed everything, to 33 hours of interviews distilled into two, Cramer unpacks what harm reduction looks like on film, why he lost sleep over who might watch the movie and act recklessly, and what capitalism and biopiracy mean for the sacred plants at the center of this revival. Journeys is available now on Apple TV, Amazon, Google Play, YouTube, and Vimeo.

On this episode, host Jim Tate sits down with Chris Pauli, Co-Founder and Molecular Biologist at Tryptomics, a Colorado-based biotech laboratory pioneering testing and research services for psychoactive plants and fungi. From his early work sequencing the cannabis genome to building one of the first dedicated psychedelic testing labs, Pauli brings a rigorous scientific lens to a field that urgently needs one. The conversation covers the extraordinary variability in psilocybin potency across mushroom strains and flush cycles; the case for full-spectrum "ensemble" medicine over single-compound isolates; the emerging science of pharmacogenomics and what it could mean for personalized psychedelic therapy; Colorado's landmark Natural Medicine Health Act (Proposition 122) and the regulatory challenges ahead for ibogaine and DMT; and the troubling proliferation of synthetic tryptamines in the unregulated market.

S1E18: Ontological Shock and the Healing Threshold: A Psychedelic Clinician’s Field Guide with Peter Addy, PhD.

Join host Jim Tate sits and his guest psychedelic researcher and psychotherapist Peter Addy, PhD for an honest, nuanced, and scientifically grounded survey of the current psychedelic landscape. From the mechanics of harm reduction and integration therapy to the politics of federal scheduling, the conversation moves fluidly between clinical science, cultural history, and personal experience.

He addresses the promise and peril of the commercial psychedelic industry, reflects on Oregon’s pioneering psilocybin services framework, examines the FDA’s rejection of MDMA-assisted psychotherapy, and shares first-hand accounts from his clinical work with chronic pain patients. He also draws on deep field experience studying Salvia divinorum, including travel to Oaxaca, Mexico and years of postdoctoral research at Yale. Equal parts scholar, clinician, and thoughtful advocate, Dr. Addy offers a rare combination of scientific rigor and compassionate practice.

S1E17: Healing From the Inside Out: Bénédicte Mannix on Psilocybin, Mental Homeostasis, and the Art of the Private Retreat

Join host Jim Tate and his guest Bénédicte (Ben) Mannix , holistic psilocybin therapist, sophrotherapist, and founder of Sophrodelic in Kingston, Jamaica for a candid and illuminating conversation about what truly personalized psychedelic-assisted therapy looks and feels like in practice.

S1E16: Clearing the Plaque: How DMT Saved One Man's Life and What Science Is Beginning to Confirm

Join host Jim Tate and his guest DMT Field Guide author Adam Butler, psychedelic philosopher, prolific author, and passionate DMT advocate , for a candid, deeply personal conversation at the intersection of mental health, neuroplasticity, and the emerging science of psychedelic medicine. Butler, author of Butler's DMT Field Guide: A Brief History, Step-by-Step Recipes, and Personal Experiences From a DMT Saturated Consciousness, shares how N,N-dimethyltryptamine pulled him back from the edge of suicide and addiction, and why he believes, with growing scientific backing that this endogenous molecule may hold keys to treating everything from depression and PTSD to stroke and dementia. From harm reduction and ontological risk to extended-state DMT research, microdosing philosophy, and the urgent need for philanthropic investment in psychedelic science, this episode maps the terrain for anyone curious about the revival happening at the frontier of mind, medicine, and healing.

S1E15: The People's Mushroom: Psychedelics, Policy, and the Push to Reclaim Scotland's Indigenous Apothecary with Anna Ross, PhD

Join host Jim Tate travels north of the border to speak with Dr. Anna Ross, lecturer at the University of Edinburgh, co-founder of the Scottish Psychedelic Research Group (SPRG), and self-described "lived and living experience researcher" who came up through Scotland's 1990s rave scene. Dr. Ross traces the founding of SPRG, Scotland's rich but under-documented relationship with indigenous psychoactive plants, the conspicuous absence of clinical psychedelic trials north of England, the thorny politics of Compass Pathways and IP enclosure in the psychedelic space, and the underground scene that has quietly thrived for decades. She also opens up about her own encounters with DMT and her ongoing research focus: ontological shock, the profound and sometimes destabilizing worldview ruptures that psychedelics can produce, and which mainstream psychiatry still struggles to name, let alone treat. A rich, candid, and highly informed conversation from the northern edge of the psychedelic renaissance.

S1E14: Extended-State DMT (DMTx) Method

Join host Jim Tate and his guest Daniel McQueen, a professional psychedelic therapist and executive director of the Center for Medicinal Mindfulness, a psychedelic harm-reduction program and international psychedelic therapy training program focusing on Cannabis-Assisted Psychedelic Therapy and Cannabis-Assisted Psychotherapy. McQueen discusses his journey from underground guide to regulated access work in Colorado, his experiments extending DMT experiences via infusion, his views on psilocybin regulation, and the tensions inherent in commodifying sacred medicines.